VIROLOGY
182, 371-375
lmmunogenicity
WILLEM
(1991)
of Peptides
P. A. POSTHUMUS,
Simulating
a Neutralization
Epitope of Transmissible
*a’ JOHANNES A. LENsTr#,t ANTON P. VAN NIEUWSTADT,
AND ROB H. MELOEN*~’
BERNARD A. M. VAN DER ZWT,t
*
Gastroenteritis
Virus
WIM M. M. SCHAAPER, *
*Central Veterinary Institute, P. 0. Box 65, 8200 AB Lelystad, and t Institute of Infectious Diseases and Immunology.
School of Veterinary Medicine, University of Utrecht, P.O. Box 80.165, 3508 TD Utrecht, The Netherlands
Received September
17, 1990. accepted
January 9, 1991
Previously, an epitope recognized by a set of neutralizing monoclonal antibodies directed against the S protein of
transmissible
gastroenteritis
has been identified. This neutralization
epitope can be simulated by a single peptide
combining residues 380 to 387 and 1176 to 1184 of the S protein; this combination peptide (SFFSYGEI-QLAKDKVNE)
was more antigenic than its single constituents.
Here we describe the immunogenicity
of this combination peptide, in
comparison with monomer and tandem peptides of both constituents,
and with a cyclic peptide consisting of residues
373 to 398. All antisera, raised in rabbits, bound to the peptide used as immunogen. Only sera that recognized the
residues 380 to 387 bound to whole virus. Three of the four antisera with the highest binding titers to whole virus also
had neutralization
activity. Analysis of the fine-specificity
of the antisera with PEPSCAN peptides indicated that the
spectrum of antibodies induced by the 380 to 387 sequence depended on the presentation
of this sequence in a
peptide to the immune system. The nonbinding and nonneutralizing
anti-(380 to 387)-sera appeared to contain a
limited spectrum of antipeptide antibodies. Furthermore, the lack of neutralization
of the antiserum against the combination peptide could be explained by the immunodominance
in rabbits of the 1176 to 1184 sequence over the 380 to
387 sequence. These findings demonstrate a few fundamental problems of simulating discontinuous
epitopes by single
o iSSi Academic
press, IIK
synthetic peptides.
raised in rabbits, against the combination
peptide
SFFSYGEI-QLAKDKVNE,
against the monomer and
tandem peptides of both constituents, and against a
cyclic peptide consisting of residues 373 to 398. The
binding of the antipeptide sera to viral antigen was determined in an ELISA and in a virus neutralization assay
(7). PEPSCAN analysis was used to determine the
fine-specificity of the binding of the antipeptide sera to
the peptides (7). This fine-specificity was then correlated with the ability of the antipeptide sera to bind to
whole virus and to neutralize virus infectivity.
Peptide synthesis and immunization of rabbits were
as described (7). Table 1 lists the sequences of the
peptides, designated A, B, C, D, E, and F. A cysteine
residue was added at the C terminus of the peptides B,
C, D, E, and F to couple the peptide to keyhole limpet
hemocyanin.
Peptide A was oxidized to form cyclic
monomers via a disulfide bridge between the N- and
C-terminal cysteine; this peptide was used to immunize two rabbits without coupling to a carrier protein.
The antipeptide sera, designated CY-A,,~,a-B,,, , WC,,,,
4,2,
a-E,,,, and CY-F,,,, were collected 77 days after
immunization (Table 2).
The binding of the antipeptide antibodies with the
peptides used for immunization
was tested by an
ELISA with coated peptides (Table 2) and with peptides covalently bound to a solid support; the PEP-
Transmissible
gastroenteritis
virus (TGEV) is a
member of the Coronaviridae family. It causes enteric
disease in pigs of all ages with high mortality for newborn piglets ( 1, 2). Neutralizing antibodies are elicited
by the spike protein S (1447 amino acids), which is
located on the viral surface (3, 4). Mutual competition
of neutralizing
monoclonal antibodies (MAbs) indicated that five antigenic sites of the S protein are involved in neutralization (Refs. (5-7); L. Enjuanes, personal communication).
The binding of MAbs specific
for one of these sites (group IV) to short overlapping
peptides derived from the S amino acid sequence revealed an epitope that consisted of the residues 380 to
387 with contributions
of residues from the region
1 176 to 1 184 (7). The combination peptide SFFSYGEI-QLAKDKVNE,
which contained the residues of
both regions was a better antigen than each of its constituents. One MAb of this group IV, CVI-TGEV-57.57
(MAb 57.57), strongly binds to whole virus, has a high
neutralizing activity, and recognizes peptides from the
S protein residue regions 378 to 389 and 1 173 to 1 187
and the combination peptide (7). In this study we describe the biological properties of antipeptide sera,
’ Present address: Virological R & D Department, lntervet International, P.O. Box 31, 5830 AA. Boxmeer, The Netherlands.
’ To whom requests for reprints should be addressed.
371
0042.6822/91
$3.00
CopyrIght 0 1991 by Academtc Press. Inc.
All rights of reproduction
MI any form reserved
SHORT COMMUNICATIONS
372
TABLE 1
SEQUENCESOF THE PEPTIDESUSED FOR IMMUNIZATIONAND PEPSCAN
Peptide
Designation of
antipeptide serum
Sequences
A
CMVSDSSFFSYGEIPEGVTDGPRYC
B
C
D
E
F
-
SFFSYGEI-C
SFFSYGEI-SFFSYGEI-C
QLAKDKVNE-C
QLAKDKVNE-QLAKDKVNE-C
SFFSYGEI-QLAKDKVNE-C
QLAKDKVNE-SFFSYGEI
Designation of
PEPSCAN peptidesb
ol-A
B -C is a nonsequential cysteine residue at the C terminus of the peptides, used to couple the peptides to keyhole limpet hemocyanin
coupling agent m-maleimidobenzoyl-l\/-hydroxysuccinimide
ester.
b The PEPSCAN peptides were synthesized without an additional cysteine residue.
SCAN analysis (Fig. 1 ). Antibodies raised against peptides A, B, and C bound to peptides that contained the
SFFSYGEI sequence (peptides A, B, C, b, c, F, and f ‘)
and not to peptides
that contained
only the
QLAKDKVNE sequence (peptides D, E, d, and e). Conversely, antibodies raised against peptides D and E
bound to peptides D, E, F, d, e, f, and f ’ and not to
TABLE 2
ANTIVIRALAND ANTIPEPTIDETITERSOF 12 ANTIPEPTIDESERA~
Peptide ELISA“
Antipeptide
serum
Virus
ELISAb
Virus
neutralizationC
A
B
C
D
E
F
3.6
3.0
5.1
4.9
4.5
5.0
<
<
3.6
3.1
5.0
4.8
4.6
5.0
<
<
<
<
2.5
3.3
6.2
<
<
<
<
<
<
4.9
4.3
4.2
4.1
3.7
4.3
4.8
<
<
<
<
<
<
4.9
4.6
4.3
4.3
3.8
4.4
4.6
3.7
3.2
4.2
3.8
3.4
4.3
5.0
4.4
4.1
4.3
4.0
4.4
6.4
(Y-A,
LX-A,
(Y-B,
LY-B,
WC,
WC,
(Y-D,
a-D*
4.3
3.7
4.2
3.3
<
4.1
<
<
2.4
1.2
<
<
2<6
<
<
4.4
3.8
3.9
3.8
3.4
4.3
<
<
WE,
CPE,
(Y-F,
<
<
<
<
<
<
<
<
2.3
2.9
6.8
<
<
3.7
3.1
3.5
6.5
2.9
3.5
6.2
a-F,
MAb 57.57
BTiters are expressed as the -log,,, of the serum dilution. The
antipeptide sera were collected 77 days after immunization. Each
peptide (see Table 1) was used to immunize two rabbits.
’ <, virus ELISA titer is ~2.0.
c <, virus neutralization titer GO.9. The neutralization was assayed
in a microdilution system with SK6 cells, the Purdue strain of TGEV,
and serial dilutions of the antisera starting at a dilution of 1:8 (7).
d Peptides A, B, C, D, E, and F were coated onto the wall of a well
of a microtiter plate (1 pg). The binding of the antipeptide sera were
tested in an ELISA, starting at a serial dilution of 1: 1O3(7). <, peptide
ELISA titer is ~2.0.
via the
peptides A, B, C, b, and c. In the peptide ELISA all
antisera had similar titers with the peptides used as
immunogen. However, with PEPSCAN peptides the (YD,,, sera and WE,,, sera have been diluted 10 times
more than the a-A,,*, ‘Y-B,,~, t-C,,., and ‘Y-F,,, sera to
obtain an equal degree of binding. Furthermore, the
CX-F,,~sera against the combination peptide bound better to the peptides D, E, d, and e than to B, C, b, and c
(Table 2; Fig. 1). Apparently, the QLAKDKVNE sequence alone or in combination with the SFFSYGEI sequence is in rabbits more immunogenic
than the
SFFSYGEI sequence. Changing the order of the constituents
of the combination
peptide SFFSYGEIQLAKDKVNE
(f) into the peptide QLAKDKVNESFFSYGEI (f ‘) did not significantly influence the binding pattern of the antipeptide sera (Fig. 1). Essentially
the same results were obtained when the constituents
of the tandem and combination peptides were separated by a spacer of one, two, or three glycine residues
(data not shown).
The binding and neutralization properties of the antipeptide sera to whole TGEV are shown in Table 2. Only
antisera that recognized the peptides A, B, C, and F
(sera (Y-A,,*, a-B,,,, a-C,, and a-F,,,) showed binding
to the virus. The (Y-C, serum is exceptional because it
bound to peptides A, B, C, and F but not to whole virus.
The highest titers of binding to whole virus were observed with the a-A,, a-A,, a-B,, and a-C, sera. Three
of these sera (WA, , WA,, and a-C,) had neutralization
activities that correlated with their binding titers to
whole virus. The (Y-D,,~ and WE,,, sera did not recognize whole virus nor did they have any neutralization
activity. Therefore, we conclude that only antibodies
specific for the S protein residues 380 to 387 (SFFSYGEI) bind to virus and may have neutralization activity.
This is in agreement with the observation that antipep-
SHORT COMMUNICATIONS
MAb
b
c
d
PEPSCAN
e
f
PePtlaeS
SFFSYGEI-SFFSYGEI-C
b
f
ta
e
f
!aemldeD
QLAKDKVNE-C
ea a-q
QLAKDKVNE-QLAKDKVNE-C
Eaa-E,
c
d
PWSCAN
(0
mm-c*
Ea a-c,
57.57
(E)
a-E2
2,
0)
m
a-D2
SFFSYGEI-QLAKDKVNE-C
Ei
S-F,
m
f
O=)
CT-F*
I
b
c
d
PEPSCPN
e
f
pepMeS
f
I
b
c
d
PEPSCAN
e
PmdeS
f
f
FIG. 1. The sequence of the peptides b, c, d, e, f, and f ‘are given in
Table 1. The first plot shows the binding of MAb CVI-TGEV-57.57,
diluted 1 :l 06. On top of each next plot the peptides used as immunogen and the antisera from two rabbits are indicated. The antibody
binding, measured as the extinction at 405 nm by an ELISA (A,,,), is
plotted vertically. The antipeptide sera wA,,~, a-B,,, , WC,,, , and (YF,,, were diluted 1: 10’ and the sera a-D,,, and WE,,, were diluted
1:103.
tide sera against the residues 377 to 391 had neutralization activity while antipeptide sera against residues
1171 to 1185 did not bind to whole virus and had no
neutralization activity ( 7).
To explain most of the biological properties of the
antipeptide sera a-A to a-F, we determined their finespecificities
using PEPSCAN peptides. Overlapping
peptides that vary in length from three to nine amino
acids derived from the regions 372 to 389 and 1166 to
1201 (Fig. 2) were synthesized on polyethylene rods
and tested as described previously (7, 8). Each first
peptide of length N consisted of the first N amino acids
of the specified regions. Subsequent peptides contained the last N - 1 amino acids of the preceding
peptide and the next amino acid of the specified re-
373
gion. Antibody binding was measured as the extinction
at 405 nm by an ELISA and plotted vertically. The binding patterns of the antipeptide sera were compared
with the binding patterns of MAb 57.57. Our experience indicates that the differences in specific binding
of the antipeptide sera are both reproducible and significant.
The recognition patterns obtained with the tri- to
nonapeptides of the 372 to 389 region (Fig. 2A) indicate that WA,,,, O-B,,,, WC,,,, and a-F,,, antipeptide
sera contain a broad spectrum of antibodies. Apparently, this depends more on the presentation of the
380 to 387 sequence-as
a cyclic (A), a coupled monomer (B), a coupled tandem (C), or a coupled combination (F) peptide-than
on the individual rabbit (from an
outbred population) used for immunization. Most antipeptide sera recognized shorter peptides than the antiviral MAb 57.57.
A most significant observation may be that some of
the binding patterns seem to reflect a limited paratope
specificity (a limited spectrum of antibodies). This was
observed previouslywith antipeptide sera that can neutralize foot-and-mouth disease (FMD) virus infectivity
(8). Thus, apart from the high background, the a-B,
serum appears to contain mainly antibodies that bind
specifically to the heptapeptide
FFSYGEI (residues
381 to 387) and also to the shorter derivatives
FFSYGE, FSYHE, YGEI, and GEI. Likewise, a-B, binds
to peptides that start with the residues FFS and shows
again an optimal binding to FFSYGEI. The recognition
of peptides starting with the sequence VSDS (376 to
379) must be aspecific since these residues are not
part of the peptide immunogen (Fig. 2A). The WC,
serum shows a binding pattern that is typical for a
monoclonal antibody [cf. (7, 9)], while the pattern of
the a-F, serum is remarkably similar to the pattern of
MAb 57.57. It is of interest that these monospecific
antipeptide sera are nonneutralizing or, as a-C,, do not
even bind to whole virus. In contrast, the neutralizing
antipeptide sera ‘Y-A,,, and LY-& have clearly a more
complex recognition pattern. This suggests an explanation for the different biological properties of the set of
antipeptide sera: a heterogeneous immune response
raised against a peptide is more likely to contain neutralizing antibodies than a monospecific response.
Apparently,
binding of antibodies to whole virus
does not necessarily imply neutralization. This is also
indicated by our previous finding that not all MAbs that
bind to the 376 to 389 region of the S protein have
neutralization ability and that the neutralizing and nonneutralizing MAbs have different fine-specificities
(7).
The CU-F,antiserum raised against the combination
peptide has a specificity that is remarkably similar to
374
SHORT COMMUNICATIONS
MAb 57.57
A
3
4
5
6769
SFFSYGEI-C
QUKDKVNE-QLAKDKVNE-C
3
4
3
56789
4
56789
3
4
5
6
7
8
9
SFFSVGEI-QAKDKVNE-C
2r
3
4
56789
-34
5
6
789
FIG. 2. Binding of antipeptide
antibodies with overlapping PEPSCAN peptides that vary in length from three to nine amino acids. The antibody
binding, expressed as the extinction at 405 nm by ELISA, is plotted vertically and the numbers below the horizontal axis correspond to the
number of amino acids present in the peptides. The sequence of the peptide immunogen is shown above each pair of scans. (A)The PEPSCAN
peptide sequences are derived from the S protein sequence region 372 to 389. Boldface lines indicate the peptides with N-terminal amino acid
380. At the top the recognition pattern of MAb CVI-TGEV-57.57 (diluted 1:3 X 104) is given (7). The other recognition patterns, in pairs, are of
the antipeptide sera wA,,~, a-B,,,, (Y-C,,~, and a-F,,, respectively (each diluted 1 :l 03). (B) The PEPSCAN peptide sequences are derived from
the S protein sequence region 1 166 to 1201, Boldface lines indicate the peptides with N-terminal amino acid 1176. At the top the recognition
pattern of MAb 57.57 (diluted 1:5 x 103) is given (7). The other recognition patterns, in pairs, are of the antipeptide sera a-D,,,. WE,,, , and a-F,,,
respectively (each diluted 1: 10 3,
the pattern of the neutralizing MAb 57.57 (Fig. 2A).
However, the binding titer of (y-F2 is about lo4 times
lower than the titer of MAb 57.57. Therefore, the low
virus titers and the lack of neutralization (Table 2) can
be explained by the low concentration
of antibodies
with a high affinity for the SFFSYGEI sequence. As
suggested by the data in Table 2 and Fig. 1, this is
most likely caused by the immunodominance
of the
1 173 to 1 184 sequence in rabbits.
The immunodominance
of this 1173 to 1184 sequence is also indicated by the PEPSCAN patterns of
the antipeptide sera a-D,,,, (Y-E,,~, and ‘Y-F,,~ with the
tri- to nonapeptides
of the 1166 to 1201 sequence
(Fig. 2B). The recognition of several overlapping tripeptides by the (Y-D,,, and (Y-F,,~ sera clearly reflects
the presence of a broad antibody spectrum. The a-F,,,
responses appear to contain a limited antibody spectrum, but none of the patterns resembles the pattern of
MAb 57.57.
The use of synthetic peptides that combine linear
antigenic sites to mimic a discontinuous epitope is a
logical approach to induce antibodies that bind to virus
and have neutralization activity. Various attempts were
made to combine antigenic peptides that are separated on the primary sequence but are in close range in
the tertiary structure. A combination peptide of the two
epitopes of FMD virus that contains the residues of the
regions 140 to 160 and the C terminus (residues 200
to 213) of VP, induced high neutralizing antibodies in
guinea pigs ( 10). Recently, Francis and co-workers
have shown that combination
peptides of the sequence of the major epitope of two different FMD virus
strains can elicit weak to moderate neutralizing antibodies in guinea pigs ( 7 1).
Our findings, however, reveal some of the problems
with the design of complex peptide antigens that
mimic a discontinuous epitope. Notably, the induction
of antipeptide antibodies with a virus neutralization activity may depend on the presentation of the peptide
sequence. We have demonstrated that a detailed in-
SHORT COMMUNICATIONS
vestigation of the fine-specificity of antipeptide sera by
PEPSCAN analysis can contribute to an explanation of
their biological properties. This may be most relevant
for the investigation of the effect of peptide vaccination
in the natural host.
ACKNOWLEDGMENTS
We thank Wouter C. Puijk and Henk H. Plasman for performing the
synthesis of the PEPSCAN peptides, Douwe Kuperus and Hans W.
Westra for performing the ELISA assays, Peter Brie1 for the synthesis
of the peptides on milligram scale, and Tiety Zetstra and Jan Boonstra for performing the serological assays. This work was supported
by a grant from the NW0 Council for Medical and Health Research
(Grant 900-515-002).
REFERENCES
1. SIDDELL, S.. WEGE, l-l., and TER MEULEN, V., /. Gen. Viral. 64,
761-776 (1983).
2. STURMAN. L. S., and HOLMES, K., Adv. Virus Res. 28, 35-1 12
(1983).
375
3. JIM~NEZ, G., CORREA, I., MELGOSA, M. P., BULLIDO, M. J., and
ENJUANES,L., /. L%o/. 60, 131-139(1986).
4. LAUDE, H., CHAPSAL,J. M., GELFI, J., LABIAU, S., and GROSCLAUDE,
J., J. Gen. Viral. 67, 119-130 (1986).
5. CORREA, I., JIM~NEZ, G., Sufiri, C.. BULLIDO, M. J., and ENJUANES,
L., Virus Res. 10, 77-94 (1988).
6. DELMAS, B., GELFI, J., and LAUDE, H., J. Gen. Lhol. 67, 14051418 (1986).
7. POSTHUMUS,W. P. A., LENSTRA,J. A., SCHAAPER,W. M. M., VAN
NIEUWSTADT, A. P., and MELOEN, R. H., /. Viral. 64. 33043309 (1990).
8. GEYSEN, H. M., BARTELING,S. J., and MELOEN, R. H., Proc. Nat/.
Acad. Sci. USA 82, 178-l 82 (1985).
9. KUSTERS,J. G., JAGER,E. J., LENSTRA,J. A., KOCH, G.. POSTHUMUS,
W. P. A., MELOEN, R. H., and VAN DER ZEIJST. B. A. M., /. Immunol. 143, 2692-2698 (1989).
10. DIMARCHI, R., BROOKE,G.. GALE, C.. CRACKNEL,V., DOEL, T., and
MOWAT, N., Science 232, 639-641 (1986).
11. FRANCIS, M. J., HASTINGS, G. Z., CLARKE, B. E., BROWN, A. L.,
BEDDELL, C. R., and ROWLANDS, D. J., immunology 69, 171176 (1990).